Efficacy and safety of Chlorpromazine in the treatment of COVID-19 patients
Phase 2
- Conditions
- COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200913048708N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
all admitted patients with covid -19 infection based on clinical findings ,PCR or lung CT abnormality consistent with covid-19
spo2 bellow 93 mmHg
age above 18 years old
Exclusion Criteria
patient rejection
history of antipsycotic use
history of seizure, dementia and parkinson disease
Hx of liver disease
Hx of feochromocytoma
allergy to phenothiazines drug
any drug interaction between patients medicines and chlorpromazine
pregnancy and lactation
Hx of covid treatments
bradycardia < 60 /min
multi-organ failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patients level of Spo2. Timepoint: daily. Method of measurement: puls oximetr.
- Secondary Outcome Measures
Name Time Method eed to ICU admission. Timepoint: During the study. Method of measurement: Follow up of patient and documentation of the ICU admission.;Days stayed in the Intensive Care Unit. Timepoint: During the study. Method of measurement: Documenting the days stayed in the Intensive Care Unit.;Days stayed in the hospital. Timepoint: At the end of the study. Method of measurement: Documentation of the hospital stay according to patients chart.;Mortality rate. Timepoint: At the end of the study. Method of measurement: Follow up of patients and documentation of the mortality.